Stock ALBPS BIOPHYTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News Biophytis S.A.

Equities

ALBPS

FR0012816825

Market Closed - Euronext Paris
Other stock markets
 11:35:04 2024-04-17 am EDT 		5-day change 1st Jan Change
0.0023 EUR -8.00% Intraday chart for Biophytis S.A. -17.86% -54.90%
Apr. 17 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Apr. 16 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
MT
French Biotech Biophytis Files Patent Application for BIO101
MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT
Biophytis: patent application filed in the field of obesity
CF
Biophytis S A : Press Release
PU
Biophytis S A : dépose une demande de brevet et renforce sa propriété intellectuelle dans l’obésité
PU
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
MT
ADRs Close Lower; VIA Optronics AG Declines 30%
DJ
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
MT
ADRs End Higher; Biophytis Climbs 30%
DJ
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
MT
Top Premarket Gainers
MT
Biophytis launches clinical study in obesity
CF
Biophytis Flags 'Significant Doubt' Over Ability to Continue Operations; to Launch Phase 2 Obesity Trial; Shares Rise Pre-Bell
MT
Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)
CI
Biophytis S A : lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
PU
Biophytis S A : annonce ses résultats financiers 2023 et fait le point sur ses activités
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALBPS Stock
  4. News Biophytis S.A.